[go: up one dir, main page]

PE20110931A1 - Pirrolidin-2-onas como ligandos de hdm2 - Google Patents

Pirrolidin-2-onas como ligandos de hdm2

Info

Publication number
PE20110931A1
PE20110931A1 PE2011000624A PE2011000624A PE20110931A1 PE 20110931 A1 PE20110931 A1 PE 20110931A1 PE 2011000624 A PE2011000624 A PE 2011000624A PE 2011000624 A PE2011000624 A PE 2011000624A PE 20110931 A1 PE20110931 A1 PE 20110931A1
Authority
PE
Peru
Prior art keywords
pyrrolidin
methyl
indol
carboxamide
chlorophenyl
Prior art date
Application number
PE2011000624A
Other languages
English (en)
Inventor
Christoph Burdack
Cedric Kalinski
Guenther Ross
Lutz Weber
Vladimir Khazak
Original Assignee
Priaxon Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Priaxon Ag filed Critical Priaxon Ag
Publication of PE20110931A1 publication Critical patent/PE20110931A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE PIRROLIDIN-2-ONA DE FORMULA (I), DONDE V ES C=O, C=S O CH2; X ES S, O, CH2, NH, ENTRE OTROS; Y ES CO, COO, CH2O, CH2CO, ENTRE OTROS; n ES UN ENTERO DE 0 A 3; R1, R2, R3, R4, R5, R7 Y R8 SON H, ALQUILO C1-C20, ALQUENILO C2-C20, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: CIS-2-(6-CLORO-1-METIL-1H-INDOL-3-IL)-1-[(4-CLOROFENIL)METIL]-3-[(4-METILFENIL)SULFANIL]-5-OXO-N-(PIRIDIN-2-ILMETIL)PIRROLIDIN-3-CARBOXAMIDA, CIS-2-(6-CLORO-1-METIL-1H-INDOL-3-IL)-1-[(4-CLOROFENIL)METIL]-3-[(4-METILFENIL)SULFANIL]-5-OXO-N-(TIOFEN-2-ILMETIL)PIRROLIDIN-3-CARBOXAMIDA, CIS-2-(6-CLORO-1-METIL-1H-INDOL-3-IL)-1-(4-CLOROFENIL)-3-[(4-METILFENIL)SULFANIL]-5-OXO-N-(PIRIDIN-2-ILMETIL)PIRROLIDIN-3-CARBOXAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON LIGANDOS DE UNION A LA PROTEINA HDM2 QUE INDUCEN LA APOPTOSIS Y LA INHIBICION DE LA PROLIFERACION Y SON UTILES EN EL TRATAMIENTO DEL CANCER
PE2011000624A 2008-09-15 2009-09-15 Pirrolidin-2-onas como ligandos de hdm2 PE20110931A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9696408P 2008-09-15 2008-09-15
EP08016236 2008-09-15

Publications (1)

Publication Number Publication Date
PE20110931A1 true PE20110931A1 (es) 2012-01-25

Family

ID=40303570

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000624A PE20110931A1 (es) 2008-09-15 2009-09-15 Pirrolidin-2-onas como ligandos de hdm2

Country Status (14)

Country Link
US (2) US8119623B2 (es)
EP (1) EP2346852B1 (es)
JP (1) JP5701758B2 (es)
KR (1) KR20110063542A (es)
CN (1) CN102149708A (es)
AR (1) AR073578A1 (es)
AU (1) AU2009291155A1 (es)
BR (1) BRPI0918603A2 (es)
CA (1) CA2736295A1 (es)
EA (1) EA201100483A1 (es)
NZ (1) NZ591073A (es)
PE (1) PE20110931A1 (es)
TW (1) TW201011009A (es)
WO (1) WO2010028862A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
AU2009308687A1 (en) * 2008-11-03 2010-05-06 Chemocentryx, Inc. Compounds for the treatment of osteoporosis and cancers
ES2528948T3 (es) 2009-09-21 2015-02-13 Chemocentryx, Inc. Derivados de pirrolidinona carboxamida como moduladores de quemerina-R (ChemR23)
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
SG10201505700QA (en) 2010-04-22 2015-08-28 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US10822374B2 (en) 2010-11-12 2020-11-03 Dana-Farber Cancer Institute, Inc. Cancer therapies and diagnostics
CA2829188C (en) 2011-03-10 2016-10-18 Daiichi Sankyo Company, Limited Dispiropyrrolidine derivatives
WO2013025939A2 (en) * 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
US9505775B2 (en) 2012-11-03 2016-11-29 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
CN105121407B (zh) 2013-02-28 2017-07-18 美国安进公司 用于治疗癌症的苯甲酸衍生物mdm2抑制剂
MX374513B (es) 2013-03-14 2025-03-06 Amgen Inc Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
AU2014352875B2 (en) 2013-11-22 2019-10-24 CL BioSciences LLC Gastrin antagonists (eg YF476, netazepide) for treatment and prevention of osteoporosis
US10138251B2 (en) 2014-04-11 2018-11-27 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
EP3150578B1 (en) 2014-05-29 2020-10-14 Mitsubishi Tanabe Pharma Corporation Novel pyrrolidine compound and application as melanocortin receptor agonist
US10576064B2 (en) 2014-07-03 2020-03-03 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
EA038071B1 (ru) 2014-08-21 2021-07-01 Бёрингер Ингельхайм Интернациональ Гмбх СОЕДИНЕНИЕ СПИРО[3H-ИНДОЛ-3,2'-ПИРРОЛИДИН]-2(1H)-ОНА И ЕГО ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ MDM2-p53
WO2016100823A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
EP3260119B1 (en) 2015-02-20 2023-11-15 Daiichi Sankyo Company, Limited Combination method for treating cancer
CA2982435C (en) 2015-04-13 2020-05-26 Daiichi Sankyo Company, Limited Treatment method by combined use of mdm2 inhibitor and btk inhibitor
CA2991099A1 (en) 2015-07-02 2017-01-05 Horizon Orphan Llc Ado-resistant cysteamine analogs and uses thereof
UA123905C2 (uk) 2015-10-09 2021-06-23 Бьорінгер Інгельхайм Інтернаціональ Гмбх Спіро[3h-індол-3,2'-піролідин]-2(1h)-онові сполуки та похідні як інгібітори мdm2-p53
WO2017090743A1 (ja) * 2015-11-27 2017-06-01 田辺三菱製薬株式会社 新規イミダゾール化合物およびメラノコルチン受容体作動薬としての用途
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
US20190240210A1 (en) 2016-10-17 2019-08-08 Daiichi Sankyo Company, Limited Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor
MX2019011945A (es) 2017-04-05 2019-11-28 Boehringer Ingelheim Int Terapia de combinacion contra cancer.
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN114558002A (zh) * 2022-03-15 2022-05-31 四川轻化工大学 化合物在制备治疗肿瘤药物中的应用
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361759A (en) * 1963-10-07 1968-01-02 Upjohn Co 3-(2-pyrrolidinyl)-indoles and method of preparation
US4219560A (en) * 1978-04-17 1980-08-26 Sandoz, Inc. Piperidine and pyrrolidine alcohols
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
EP1180513A4 (en) 1999-04-28 2002-07-10 Takeda Chemical Industries Ltd Cyclic amide compounds, process for the preparation of the same and uses thereof
JP2009542666A (ja) * 2006-06-30 2009-12-03 シェーリング コーポレイション Ｐ５３活性を増加させる置換ピペリジンおよびその使用
US7977358B2 (en) * 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives

Also Published As

Publication number Publication date
AU2009291155A1 (en) 2010-03-18
WO2010028862A1 (en) 2010-03-18
US20120122839A1 (en) 2012-05-17
TW201011009A (en) 2010-03-16
JP2012502887A (ja) 2012-02-02
NZ591073A (en) 2012-11-30
EA201100483A1 (ru) 2011-10-31
BRPI0918603A2 (pt) 2017-06-20
AR073578A1 (es) 2010-11-17
KR20110063542A (ko) 2011-06-10
US8119623B2 (en) 2012-02-21
US9045414B2 (en) 2015-06-02
EP2346852B1 (en) 2015-02-25
JP5701758B2 (ja) 2015-04-15
US20100075949A1 (en) 2010-03-25
CA2736295A1 (en) 2010-03-18
EP2346852A1 (en) 2011-07-27
CN102149708A (zh) 2011-08-10

Similar Documents

Publication Publication Date Title
PE20110931A1 (es) Pirrolidin-2-onas como ligandos de hdm2
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
CL2009000619A1 (es) Compuestos derivados de carbazol, inhibidores de la proteina hsp90; procedimiento para preparar los compuestos; compuestos intermediarios, composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en el tratamiento del cancer.
UY31384A1 (es) Novedosos compuestos heterociclicos para la inhibicion de la proteina quinasa b
GEP201706703B (en) Boronate ester compounds and pharmaceutical compositions thereof
EA201100037A1 (ru) Органические соединения
CY1118007T1 (el) Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
EA201070247A1 (ru) Ингибиторы протеасом
EA201101699A1 (ru) Синергетические фунгицидные смеси
ATE473975T1 (de) Chemische verbindungen
ATE398613T1 (de) Chemische verbindungen
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
CY1115262T1 (el) Ανταγωνιστες trpv1 και χρησεις αυτων
PE20071114A1 (es) Compuestos de tiazol como agentes moduladores de pkb
MX346924B (es) Compuestos de diarilhidantoina.
PE20090975A1 (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma
EA201170832A1 (ru) Пуриновые соединения
EA200601766A1 (ru) Производные имидазола
EA201170997A1 (ru) Производные индола в качестве противораковых агентов
MX2024002391A (es) Inhibidores de indolina de kif18a.
CL2011000979A1 (es) Compuestos derivados ftalazina 1,4-disustituida; composicion farmaceutica; y su uso en el tratamiento del cancer.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal